Biliary Tract Neoplasms: all 492 studies

Page 2 of 5. Open to participants first (191), then studies with results posted, then the rest; newest registration first within each.

• Optimal Perioperative Pain Control in Minimally Invasive Abdominal Cancer SurgeryRecruitingNCT06731998Not applicable
• Phase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract CancerRecruitingNCT06708858Phase 2
• HX009+ IN10018 With or Without Standard Chemotherapy for Advanced Solid TumoursRecruitingNCT06708663Phase 1/2
• Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line TreatmentNot yet recruitingNCT06662877Phase 2/3
• A Single-arm, Open-label, Prospective Clinical Study of Surufatinib Combined With Immunotherapy and Chemotherapy for Unresectable or Metastatic Biliary Tract Cancer.Not yet recruitingNCT06654947Phase 2
• Circulating Tumor Mitochondrial DNA (ct-mtDNA) As a Biomarker for Biliary Tract Cancer Recurrence SurveillanceRecruitingNCT06653127
• Investigation of Predictive Biomarkers in Patients With Advanced BTC Treated With Lenvatinib Plus PembrolizumabRecruitingNCT06648057
• D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract CancerRecruitingNCT06622057Phase 3
• A Study of HRS-4642 Monotherapy or in Combination With Adebrelimab in the Treatment of Advanced Biliary Tract Tumors.RecruitingNCT06620848Phase 2
• A Study of Tumor-Treating Fields in Combination With Durvalumab and Gemcitabine/Cisplatin in Biliary Tract CancersRecruitingNCT06611345Not applicable
• Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)RecruitingNCT06564623Phase 1
• CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract CancersRecruitingNCT06548412Phase 1/2
• Chemoimmunotherapy Combined With Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Tract CancerRecruitingNCT06546969Phase 1
• Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine DifferentiationNot yet recruitingNCT06531291Phase 2
• Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer PatientsRecruitingNCT06529718Phase 2
• Consolidative Radiotherapy (CSRT) in Patients With Oligometastatic/Locally Advanced Unresectable Bilary Tract Cancer (BTC)Not yet recruitingNCT06502080Phase 2
• Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract CancerRecruitingNCT06467357Phase 3
• This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid TumorsRecruitingNCT06451497Phase 1
• A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract CancerRecruitingNCT06431490Phase 1/2
• A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)RecruitingNCT06428409Phase 1/2
• HAIC+Adebrelimab+Lenvatinib for Conversion Treatment of Potentially Resectable, Locally Advanced Biliary Tract CancerNot yet recruitingNCT06389500Phase 2
• EUS-guided CDS vs ERCP as First Line in Malignant Distal Obstruction in Borderline Disease (CARPEDIEM-2 Trial)Not yet recruitingNCT06375954Not applicable
• EUS-guided Choledochoduodenostomy vs ERCP as First Line in Malignant Distal Obstruction in Resectable Disease (CARPEDIEM-1 Trial)Not yet recruitingNCT06375928Not applicable
• Toripalimab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract CancerRecruitingNCT06362317Phase 2
• A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)RecruitingNCT06330064Phase 1/2
• Adebrelimab and a TKI in Combination With GEMOX in First-line Treatment of Advanced Biliary Tract Cancers (BTC)RecruitingNCT06320301Phase 2
• Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid TumorsRecruitingNCT06293898Phase 1
• Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract CancerRecruitingNCT06282575Phase 3
• Efficacy and Safety of Irinotecan Liposome Injection Combined With 5-FU/LV± Immunotherapy in First-line Gemsitabine + Immunoprogressive Patients With Metastatic Biliary Tract CancerRecruitingNCT06282120
• Chemotherapy Combined With Adebrelimab and Apatinib as the Perioperative Treatment in Patients With Biliary Tract CancerRecruitingNCT06280508Phase 2
• Durvalumab Combined With Surufatinib as Maintenance Therapy in Patients With Advanced Biliary Tract CancerNot yet recruitingNCT06255262Phase 1/2
• Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid TumorsRecruitingNCT06239194Phase 1/2
• AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2RecruitingNCT06219941Phase 2
• Use of Ctdna in Patients With Gastrointestinal Tract TumorsRecruitingNCT06202131
• Circulating Tumor DNA Guided Adjuvant Chemotherapy for Biliary Tract CarcinomaNot yet recruitingNCT06171321Not applicable
• Early-stage Detection of LIver, Biliary TRAct and PancReatic CancersRecruitingNCT06139042
• Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract CancerNot yet recruitingNCT06134193Phase 2
• Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)RecruitingNCT06101277Not applicable
• Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400RecruitingNCT06084481Phase 1
• Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard TherapyRecruitingNCT06065371Phase 1
• Determination of Copper and Other Trace Elements in Serum Samples From Patients With Biliary Tract CancersRecruitingNCT06060990Not applicable
• CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for RecurrenceRecruitingNCT06037980Phase 2/3
• Chemotherapy Combined With Adebrelimab and Mecapegfilgrastim in Neoadjuvant Treatment of Potentially Resectable BTCNot yet recruitingNCT06037655Phase 2
• Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract CancersRecruitingNCT06001658Phase 2
• KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary CarcinomaNot yet recruitingNCT05985707Phase 2
• Observational Monocentric Study on Biliary Tract Cancer (BABEL)RecruitingNCT05942807
• Durvalumab and Lenvatinib With or Without Chemotherapy in First-Line Treatment of Advanced Biliary Tract CancerRecruitingNCT05935579Phase 2
• The Construction of Clinical Database and Multiomics Biobank Based on a Multicentral Prospective Cohort of Benign and Malignant Biliary Tract DiseasesNot yet recruitingNCT05896956
• A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)RecruitingNCT05849480Phase 1/2
• Oncolytic Virotherapy Combined With Tislelizumab Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer (OPTIONS-05)RecruitingNCT05823987Phase 2
• Cadonilimab Plus Regorafenib and Gem-Cis Chemotherapy in Advanced Biliary Tract CancerRecruitingNCT05820906Phase 2
• Anlotinib Plus TQB2450 Combined With Nab-paclitaxel and Cisplatin as First-line Treatment for Advanced Biliary Tract CancerRecruitingNCT05812430Phase 2
• Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid TumorsRecruitingNCT05784688Phase 1/2
• Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Biliary Tract Cancer （CASTLE-08）RecruitingNCT05781074Phase 2
• First-line Trastuzumab, Gemcitabine, Cisplatin and Nivolumab in Advanced HER2- Positive Biliary Tract Cancer: a Multicenter, Open-label, Single-arm Phase Ib/II Trial (HERBOT)RecruitingNCT05749900Phase 1/2
• ctDNA Detection of MRD in Predicting Postoperative Recurrence in Biliary Tract Cancers：A Multicenter Prospective TrialRecruitingNCT05743959
• Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCCRecruitingNCT05733598Phase 2
• Impact of a European Training Program for Robotic Liver Surgery (LIVEROBOT)Not yet recruitingNCT05723705
• Personalized Medicine for Advanced Biliary Cancer PatientsRecruitingNCT05615818Phase 3
• A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid TumorsRecruitingNCT05592626Phase 1/2
• A Single-Arm Phase II Exploratory Clinical Study of Pemigatinib in the Treatment of Advanced Gastrointestinal Cancer (Excluding Biliary Tract Cancer) Patients With FGFR Alterations Who Have Failed Standard TherapyRecruitingNCT05559775Phase 2
• RC-48 Combined With GLS-010 in HER2-overexpressed Patients With Previously Treated Unresectable Biliary Tract CancerRecruitingNCT05540483Not applicable
• Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid TumorRecruitingNCT05523947Phase 1/2
• Primary Hepatobiliary Cancer Cohort of Central ChinaRecruitingNCT05520801
• Ambispective Cohort Study of Precision Medicine for Primary Hepatobiliary Cancer Based on Next-generation SequencingRecruitingNCT05520788
• Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical ResectionRecruitingNCT05517811
• A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF AlterationsRecruitingNCT05503797Phase 2
• Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)RecruitingNCT05489211Phase 2
• Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)RecruitingNCT05482893Phase 1/2
• Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)RecruitingNCT05451043Phase 2
• Study of SMT-NK Inj. Plus Pembrolizumab vs Pembrolizumab Monotherapy in Patients With Advanced Biliary Tract CancerRecruitingNCT05429697Phase 2/3
• RC48-ADC Combinatioed Envolizumab in Locally Advanced or Metastatic Biliary Tract Cancer With Positive HER-2Not yet recruitingNCT05417230Phase 2
• Envofolimab and Lenvatinib Combined With Gemcitabine Plus Cisplatin for Advanced BTC as First-Line Treatment(ENLIGHTEN)RecruitingNCT05410197Phase 2
• Olaparib with or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based ChemotherapyRecruitingNCT05222971Phase 2
• Identification of New Biomarkers for Patients With Cholangiocarcinoma and Gallbladder CancerRecruitingNCT05184400
• A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid TumorsRecruitingNCT05150691Phase 1/2
• Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract CancerRecruitingNCT05065957Phase 2/3
• AB122 Platform StudyRecruitingNCT04999761Phase 1
• Prognostic and Predictive Markers of Response to Treatment in Patients With Bile Duct Cancer: ACABi PRONOBIL StudyRecruitingNCT04935853
• Multicenter Phase 2 Study of Envafolimab in Biliary Tract CancersNot yet recruitingNCT04910386Phase 2
• Virtual Reality for GI Cancer Pain to Improve Patient Reported OutcomesRecruitingNCT04907643Not applicable
• Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid TumorsRecruitingNCT04900818Phase 1
• A Questionnaire Survey for Biliary Tract CancersEnrolling by invitationNCT04731220
• Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid TumorsRecruitingNCT04450732Phase 1
• Hepatobiliary Tumors Tissue Samples AcquisitionRecruitingNCT04445532
• Gemcitabine+ Capecitabine Vs Capecitabine in Curatively Resected Biliary Tract CancerRecruitingNCT04401709Phase 3
• Molecular Profiling of Advanced Biliary Tract CancersRecruitingNCT04318834Not applicable
• AZD6738 Plus Durvalumab in Biliary Tract CancerRecruitingNCT04298008Phase 2
• Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma PatientsRecruitingNCT03924466Phase 2
• A Phase I/II Study of Regorafenib Plus Avelumab in Solid TumorsRecruitingNCT03475953Phase 1/2
• Tissue Procurement and Natural History Study of Patients With Malignant MesotheliomaRecruitingNCT01950572
• A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid TumorsTerminatedNCT06024174Phase 1/2Results posted
• Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or BladderCompletedNCT05512377Phase 2Results posted
• Comparison of Duodenoscope With Single-use Distal Cover and the Conventional Reusable DuodenoscopeCompletedNCT05429203Not applicableResults posted
• Milademetan in Advanced/Metastatic Solid TumorsTerminatedNCT05012397Phase 2Results posted
• Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract TumorsTerminatedNCT04683939Phase 1/2Results posted
• A Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract CancerCompletedNCT04677504Phase 2Results posted
• Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 AlterationsActive, not recruitingNCT04579380Phase 2Results posted
• Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).TerminatedNCT04566133Phase 2Results posted
• A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract CancersCompletedNCT04466891Phase 2Results posted

← Biliary Tract Neoplasms overview